Theravance Biopharma
substantial opportunity for further growth | Theravance Biopharma
Company
Deck Type
Sector
Industry
Deck date
August 2023
Slide
10 of 35
Related slides by other companies
argenx SE
Results
July 2022
significant growth in patients on therapy patient | argenx SE
Genprex
Investor Presentation
October 2022
diabetic patients in need of advanced therapy | Genprex
ATAI
Investor Presentation
October 2022
summary could potentially become a paradigm shifting therapy for use disorder current standard of care for is medication therapy requiring substitutes that carry significant side effects current strategies for withdrawal support have high rates of relapse has the potential to the first best in class treatment minimizing risk | ATAI
Legend Biotech
Investor Presentation
April 2025
| Legend Biotech
Other recent decks by Theravance Biopharma
See all presentations (5 decks)
Results
May 2023
Investor Conference
April 2023
Results
February 2023
Investor Conference
November 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights